“What has been achieved in tissue engineering and regenerative medicine?” Tissue engineering and organ regeneration expert, Ekaterine Berishvili, discusses the progress, opportunities and challenges of regeneration and repair in organ transplantation.
EPITA, the scientific community dedicated to islet and pancreas transplantation, is more vibrant and productive than ever!
While preparations for the 12th EPITA Symposium & 41st AIDPIT Workshop are underway, we would like to say a BIG thank you to all our sponsors for their support. THANK YOU. #ESOT_EPITA
Update on our 12th EPITA Symposium & 41st AIDPIT Workshop! You can now find the final programme including Oral Presentations here. #ESOT_EPITA
This handbook formalises the processes associated with the preparation of ESOT CPGs, including selecting topics for new guidelines, writing and reviewing approval, dissemination, and updating. Moreover, it defines the governance of the process.
EPITA encourages applications from either diabetes physicians or nephrologists with an interest in Beta Cell Replacement Therapy or transplant surgeons.
EPITA, the European Pancreas and Islet Transplant Association, wishes to announce a call for nominations for a new Board member. The mandate of the new EPITA Board Member is 4 years (2021-2025). Given the current composition of the EPITA Board, and to ensure that all relevant specialties are represented, applications from diabetes (transplant) physicians will be
On March 5th 2021, ESOT opened a tender for a technical provider that will build the multi-organ registry. ESOT is seeking the support of additional European national authorities and expect to finalise agreement with participating countries by the end of April 2021. In addition, ESOT is establishing contacts with non-European countries and registries. read more
The abstract submission deadline for #ESOTcongress has been EXTENDED until Thursday 25th February at 23:59 CET.
Transplant patients are exceptionally vulnerable to all infections, especially COVID-19, due to immunosuppression and other co-morbidities. There is a clear need for these patients to receive the best available protection against COVID-19 and we strongly believe that they should be considered as a priority group for vaccination across Europe. Furthermore, our patients and the broader